Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Director | February 15, 2026 | February 18, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | September 08, 2023 | September 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,144 |
Reported balance
After 2026-02-15 transaction · row 1
1 source rowRow 1 · 2026-02-15 · Grant · Acquired 4,520 · Balance 29,144 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
INFINITY PHARMACEUTICALS, INC.
Report date September 08, 2023 · Filed September 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,291 |
Ending reported balance
After 2023-09-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-09 · Exercise / conversion · Acquired 768,133 · Balance 1,585,487 F1: Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date. Row 2 · 2023-09-12 · Sale · Disposed 410,196 · Balance 1,175,291 F2: Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-09 · Exercise / conversion · Disposed 768,133 · Balance 0 F1: Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date. F3: On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023. |
| Common StockSEC Table I · non-derivative | Indirect401(K) | 16,446.7945 |
Reported balance
Holding disclosure · report date 2023-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 16,446.7945 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
F2: Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
F3: On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2026 Filed Feb 18, 2026 21:15 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 4,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001375124-26-000002 · form4-02182026_040209.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,144 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:37 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 3,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004650 · form4-02192025_090259.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,624 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2026. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:03 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000848 · form4-01092024_090151.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,326 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on January 5, 2025. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| September 12, 2023 Filed Sep 12, 2023 18:20 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | SaleCommon Stock | 410,196 | $0.07 | $28,713.72 |
DisclosureSEC source: 0000899243-23-018762 · doc4.xml · nonDerivative · entry 2 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,175,291 F2 · shares: Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 09, 2023 Filed Sep 12, 2023 18:20 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | Exercise / conversionRestricted Stock Unit · Derivative | 768,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-018762 · doc4.xml · derivative · entry 4 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 768,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date. F3 · derivative.exercise_date: On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023. F3 · derivative.expiration_date: On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023. Read SEC document |
| September 09, 2023 Filed Sep 12, 2023 18:20 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | Exercise / conversionCommon Stock | 768,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-018762 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,585,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:20 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 1,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000675 · form4-01092023_090110.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,949 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on January 5, 2024. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 17:00 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 576,100 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001140361-22-001477 · form4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,100 Underlying: Common Stock · 576,100 shares Expires 2032-01-11 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on January 31, 2022 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 21:09 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 1,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000300 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on January 5, 2023. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:14 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000399 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,138 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on January 5, 2022. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 16:05 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 485,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000899243-20-034968 · doc4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,000 Underlying: Common Stock · 485,000 shares Expires 2030-12-22 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on December 31, 2020 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 17:00 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 606,250 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000899243-20-001080 · doc4.xml · derivative · entry 3 Perkins Adelene Q · CIK 0001375124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,250 Underlying: Common Stock · 606,250 shares Expires 2030-01-10 F3 · derivative.exercise_date: The option vests as to 1/48th of the shares on January 31, 2020 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 17:00 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 155,134 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-001080 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,190 F1 · shares: Represents the reporting person's 2019 contingent compensation award paid in shares of common stock in lieu of cash at the election of the Compensation Committee of the issuer's Board of Directors. F2 · balance_after: Includes 10,593 shares of common stock acquired by the reporting person on June 14, 2019 and 10,593 shares of common stock acquired by the reporting person on December 13, 2019 through participation in the issuer's Employee Stock Purchase Plan. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 16:49 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000354 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 F1 · shares: Shares are represented by restricted stock units. Shares of common stock vest in one installment on January 6, 2021. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:05 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 242,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000899243-19-017000 · doc4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Common Stock · 242,000 shares Expires 2029-01-03 F1 · date: This option was approved by the Compensation Committee of the Board of Directors of Infinity Pharmaceuticals, Inc., on January 4, 2019, contingent upon shareholder approval of the Company's 2019 Equity Incentive Plan under which the options were granted, which was approved by shareholders on June 13, 2019. F2 · derivative.exercise_date: The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| January 07, 2019 Filed Jan 10, 2019 16:51 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000640 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,364 F1 · shares: Shares are represented by restricted stock units. Shares of common stock vest in one installment on January 7, 2020. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 16:05 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 243,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000899243-19-000653 · doc4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2029-01-04 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 16:30 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | SaleCommon Stock | 5,000 | $2.82 | $14,100.00 |
DisclosureSEC source: 0000899243-18-025797 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,561 F1 · shares: The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. F2 · price: The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.80 to $2.88, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. F3 · balance_after: Includes 7,309 shares of common stock acquired by Ms. Perkins on June 16, 2018 through participation in the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 16:22 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | SaleCommon Stock | 5,000 | $2.78 | $13,890.00 |
DisclosureSEC source: 0000899243-18-006636 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,252 F1 · shares: The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 16:10 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0000899243-18-000796 · doc4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-01-08 F1 · derivative.exercise_date: The option vests as to 50% of the shares on May 25, 2018, and as to the remaining 50% of the shares on May 25, 2019. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 20:59 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 3,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-000729 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,230 F1 · shares: Shares are represented by restricted stock units. Shares of restricted common stock vest in one installment on January 5, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:06 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-18-000458 · doc4.xml · derivative · entry 3 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-01-02 F3 · derivative.exercise_date: The option vests over a period of two years in equal annual installments on the first and second anniversary of the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:06 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 69,924 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000458 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,252 F1 · shares: Represents the reporting person's 2017 contingent compensation award paid in shares of common stock in lieu of cash at the election of the Compensation Committee of the issuer's Board of Directors. F2 · balance_after: Includes 7,308 shares of common stock acquired by Ms. Perkins on December 15, 2017 through participation in the issuer's Employee Stock Purchase Plan. Read SEC document |
| July 21, 2017 Filed Jul 24, 2017 17:48 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 85,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018767 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,020 F1 · shares: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested on July 21, 2017. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 18:11 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-008299 · edgar.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,756 F1 · shares: Shares are represented by restricted stock units. Shares of restricted common stock vest in one installment on the anniversary of the grant date, May 31, 2018. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 16:47 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-17-000806 · doc4.xml · derivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2027-01-06 F1 · derivative.exercise_date: The option vests in full on January 6, 2018. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:55 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 85,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032620 · doc4.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,411 F1 · shares: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016. Read SEC document |
| October 31, 2016 Filed Apr 14, 2017 16:05 UTC Amendment | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 85,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-010314 · doc4a.xml · nonDerivative · entry 1 Perkins Adelene Q · CIK 0001375124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,220 F1 · shares: Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016. F2 · balance_after: This amendment is being filed to correct the total amount of securities beneficial owned following the reported transaction to reflect 1,809 shares of common stock purchased through the issuer's Employee Stock Purchase Plan on June 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.